Get the Stockscreener App
36.75
0.85%
-0.32
Xoma Royalty Corp stock is traded at $36.75, with a volume of 2,021.
It is down -0.85% in the last 24 hours and down -3.47% over the past month.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
See More
Previous Close:
$36.43
Open:
$36.59
24h Volume:
2,021
Relative Volume:
0.04
Market Cap:
$436.61M
Revenue:
$9.71M
Net Income/Loss:
$-29.96M
P/E Ratio:
-10.56
EPS:
-3.48
Net Cash Flow:
$-14.79M
1W Performance:
-1.34%
1M Performance:
-3.47%
6M Performance:
+80.87%
1Y Performance:
+30.92%
1-Day Range:
$36.08
$36.59
1-Week Range:
$35.91
$39.15
52-Week Range:
$18.35
$39.92
Xoma Royalty Corp Stock (XOMA) Company Profile
Name
Xoma Royalty Corp
Sector
Industry
Phone
510-204-7239
Address
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
36.12 | 440.36M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.02 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.69 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.75 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.67 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | The Benchmark Company | Buy |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-29-21 | Initiated | Aegis Capital | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-18-18 | Reiterated | H.C. Wainwright | Buy |
| Oct-17-17 | Resumed | H.C. Wainwright | Buy |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-12-17 | Initiated | H.C. Wainwright | Buy |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-16 | Reiterated | Wedbush | Outperform |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-22-15 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-10-14 | Resumed | ROTH Capital | Buy |
| Apr-29-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-11-14 | Downgrade | MLV & Co | Buy → Hold |
| Mar-05-14 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-31-13 | Reiterated | MLV & Co | Buy |
| May-09-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-14-12 | Initiated | Cowen & Co | Outperform |
| Mar-31-11 | Reiterated | MLV Capital | Buy |
| Mar-23-11 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-06-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jan-04-11 | Reiterated | Wedbush | Outperform |
View All
Xoma Royalty Corp Stock (XOMA) Latest News
Earnings visualization tools for XOMA Royalty Corporation2025 Volume Leaders & Weekly Stock Performance Updates - newser.com
Is XOMA Royalty Corporation stock bottoming outJuly 2025 Trade Ideas & Long-Term Growth Portfolio Plans - newser.com
What insider trading reveals about XOMA Royalty Corporation stockWeekly Volume Report & Verified Stock Trade Ideas - newser.com
Top chart patterns to watch in XOMA Royalty CorporationShort Setup & Daily Oversold Stock Bounce Ideas - newser.com
Short interest data insights for XOMA Royalty CorporationWeekly Trend Summary & Stock Portfolio Risk Management - newser.com
Is now a turning point for XOMA Royalty CorporationWeekly Gains Report & Capital Efficiency Focused Strategies - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for XOMA Royalty (NASDAQ:XOMA) - MarketBeat
XOMA Co. (NASDAQ:XOMAO) Short Interest Up 66.7% in September - Defense World
XOMA Royalty (NASDAQ:XOMA) Stock Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Strategies to average down on XOMA Royalty CorporationMarket Performance Report & Fast Moving Stock Watchlists - newser.com
Why XOMA Royalty Corporation (X0M1) stock attracts HNW investorsJuly 2025 Technicals & Entry Point Strategy Guides - newser.com
XOMA Royalty PFD Update: Going Back To My Original Sell Ratings (NASDAQ:XOMA) - Seeking Alpha
XOMA Royalty Corporation (NASDAQ:XOMA) On The Verge Of Breaking Even - simplywall.st
Is XOMA Royalty Corporation stock poised for growth2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Will XOMA Royalty Corporation(X0M) stock outperform value peersTrend Reversal & Expert Verified Stock Movement Alerts - newser.com
Will XOMA Royalty Corporation (X0M1) stock profit from automation waveJuly 2025 News Drivers & Weekly Chart Analysis and Trade Guides - newser.com
XOMA Royalty extends tender offer deadline for LAVA Therapeutics By Investing.com - Investing.com South Africa
XOMA Royalty extends tender offer deadline for LAVA Therapeutics - Investing.com
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - The Manila Times
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - Benzinga
75% CVR: XOMA Royalty Extends Tender Offer for LAVA, Extended to Oct. 17 - Stock Titan
Press Release: ESSA Pharma Inc. Amends Agreement With XenoTherapeutics - 富途牛牛
Press Release: XOMA Royalty Declares Quarterly Preferred Stock Dividends - 富途牛牛
Xoma announces closing of tender offer for HilleVax - MSN
What analysts say about XOMA Royalty CorporationX0M stockEx-Dividend Date Alerts & Analyze Your Portfolio Risk in Seconds - earlytimes.in
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025 - Yahoo Finance
Is XOMA Royalty Corporation still worth holding after the dipJuly 2025 Analyst Calls & High Accuracy Trade Alerts - newser.com
Will XOMA Royalty Corporation (X0M1) stock hit analyst forecastsMarket Risk Summary & Entry Point Confirmation Alerts - newser.com
What makes XOMA Royalty Corporation stock attractive to growth fundsQuarterly Profit Summary & Long-Term Safe Investment Ideas - newser.com
Analyzing XOMA Royalty Corporation with multi timeframe charts2025 Institutional Moves & Fast Moving Market Watchlists - newser.com
Published on: 2025-09-29 02:44:30 - newser.com
XOMA Royalty Corporation stock momentum explained2025 Sector Review & Safe Capital Preservation Plans - newser.com
XOMA Royalty files correction to Series B preferred stock designation By Investing.com - Investing.com Nigeria
XOMA Royalty files correction to Series B preferred stock designation - Investing.com India
Why XOMA Royalty Corporation (X0M1) stock stays on buy listsJuly 2025 EndofMonth & Free Growth Oriented Trading Recommendations - newser.com
XOMA Royalty Declares Quarterly Preferred Stock Dividends - MSN
Essa Pharma Agrees to Amend Terms to Be Acquired by XenoTherapeutics - 富途牛牛
Xoma CFO Burns sells $155,820 in shares after option exercise By Investing.com - Investing.com South Africa
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference - 富途牛牛
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics24.09.25News - Ariva
XOMA Royalty (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Xoma Royalty Corp Stock (XOMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xoma Royalty Corp Stock (XOMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hughes Owen | Chief Executive Officer |
Sep 19 '25 |
Option Exercise |
0.00 |
35,567 |
0 |
98,268 |
| BURNS THOMAS M. | SVP, Finance & CFO |
Sep 19 '25 |
Option Exercise |
0.00 |
11,846 |
0 |
34,409 |
| BURNS THOMAS M. | SVP, Finance & CFO |
Sep 22 '25 |
Sale |
35.99 |
4,330 |
155,820 |
30,079 |
| Montano Maricel Perea | Chief Legal Officer |
Sep 19 '25 |
Option Exercise |
0.00 |
3,033 |
0 |
12,134 |
| Montano Maricel Perea | Chief Legal Officer |
Sep 10 '25 |
Option Exercise |
0.00 |
9,101 |
0 |
9,101 |
| Sitko Bradley | Chief Investment Officer |
Jun 30 '25 |
Buy |
25.39 |
2,000 |
50,780 |
7,045 |
| Hughes Owen | Chief Executive Officer |
May 19 '25 |
Option Exercise |
0.00 |
53,359 |
0 |
88,338 |
| Hughes Owen | Chief Executive Officer |
May 20 '25 |
Sale |
25.38 |
25,637 |
650,667 |
62,701 |
| BURNS THOMAS M. | SVP, Finance & CFO |
May 19 '25 |
Option Exercise |
0.00 |
17,773 |
0 |
33,045 |
| BURNS THOMAS M. | SVP, Finance & CFO |
May 20 '25 |
Sale |
25.38 |
10,482 |
266,033 |
22,563 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):